ECSP014055A - Activadores de glucoquinasa que contienen hidantoina - Google Patents

Activadores de glucoquinasa que contienen hidantoina

Info

Publication number
ECSP014055A
ECSP014055A EC2001004055A ECSP014055A ECSP014055A EC SP014055 A ECSP014055 A EC SP014055A EC 2001004055 A EC2001004055 A EC 2001004055A EC SP014055 A ECSP014055 A EC SP014055A EC SP014055 A ECSP014055 A EC SP014055A
Authority
EC
Ecuador
Prior art keywords
glucoquinase
activators containing
containing hydantoin
hydantoin
activators
Prior art date
Application number
EC2001004055A
Other languages
English (en)
Inventor
Robert Alan Goodnow
Kang Le
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP014055A publication Critical patent/ECSP014055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de hidantoína que son activos como activadores de la glucoquinasa para aumentar la secreción de insulina, lo cual los hace útiles para el tratamiento de la diabetes tipo II.
EC2001004055A 2000-05-03 2001-05-03 Activadores de glucoquinasa que contienen hidantoina ECSP014055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20149800P 2000-05-03 2000-05-03

Publications (1)

Publication Number Publication Date
ECSP014055A true ECSP014055A (es) 2002-01-25

Family

ID=22746054

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004055A ECSP014055A (es) 2000-05-03 2001-05-03 Activadores de glucoquinasa que contienen hidantoina

Country Status (20)

Country Link
US (2) US6583288B2 (es)
EP (1) EP1280801B1 (es)
JP (1) JP3842131B2 (es)
KR (1) KR100505312B1 (es)
CN (1) CN1209361C (es)
AR (1) AR034253A1 (es)
AT (1) ATE304011T1 (es)
AU (2) AU5227001A (es)
BR (1) BR0110492A (es)
CA (1) CA2407428C (es)
DE (1) DE60113247T2 (es)
DK (1) DK1280801T3 (es)
EC (1) ECSP014055A (es)
ES (1) ES2248309T3 (es)
MX (1) MXPA02010746A (es)
PE (1) PE20011313A1 (es)
PT (1) PT1280801E (es)
UY (1) UY26689A1 (es)
WO (1) WO2001083478A2 (es)
ZA (1) ZA200208370B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
KR101018318B1 (ko) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
MX2007001846A (es) * 2004-08-17 2007-03-28 Hoffmann La Roche Hidantoinas sustituidas.
CA2579717A1 (en) * 2004-09-09 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
CN101312940B (zh) 2005-11-17 2012-11-14 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
FR2894962B1 (fr) * 2005-12-20 2008-03-14 Pharmamens Sarl Hydantoines a action insulinotropique
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8034819B2 (en) * 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2188276B1 (en) * 2007-08-16 2012-03-28 F. Hoffmann-La Roche AG Substituted hydantoins
CN101896469A (zh) 2007-12-20 2010-11-24 霍夫曼-拉罗奇有限公司 作为mek激酶抑制剂的取代的乙内酰脲类化合物
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
JP5513492B2 (ja) 2008-05-16 2014-06-04 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
EP2459554B1 (en) 2009-07-31 2013-09-18 Cadila Healthcare Limited Substituted benzamide derivatives as glucokinase (gk) activators
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
ES2671881B1 (es) * 2016-11-11 2019-03-25 Consejo Superior Investigacion Procedimiento de obtencion de polimeros con grupos isocianato
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren

Also Published As

Publication number Publication date
EP1280801A2 (en) 2003-02-05
AU5227001A (en) 2001-11-12
CN1427838A (zh) 2003-07-02
BR0110492A (pt) 2003-04-08
CA2407428A1 (en) 2001-11-08
KR20020093120A (ko) 2002-12-12
JP3842131B2 (ja) 2006-11-08
WO2001083478A3 (en) 2002-05-16
UY26689A1 (es) 2001-11-30
MXPA02010746A (es) 2003-03-10
EP1280801B1 (en) 2005-09-07
DE60113247D1 (de) 2005-10-13
AR034253A1 (es) 2004-02-18
US6583288B2 (en) 2003-06-24
ATE304011T1 (de) 2005-09-15
ES2248309T3 (es) 2006-03-16
CN1209361C (zh) 2005-07-06
US20010056191A1 (en) 2001-12-27
WO2001083478A2 (en) 2001-11-08
AU2001252270B2 (en) 2005-12-15
PT1280801E (pt) 2005-11-30
US6784298B2 (en) 2004-08-31
US20030225286A1 (en) 2003-12-04
CA2407428C (en) 2010-02-02
PE20011313A1 (es) 2001-12-28
ZA200208370B (en) 2004-01-26
JP2003531905A (ja) 2003-10-28
DK1280801T3 (da) 2006-01-23
KR100505312B1 (ko) 2005-08-04
DE60113247T2 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
UY26689A1 (es) Activadores de glucocinasa que contienen hidantoina
UY26694A1 (es) Activadores de fenil glucocinasa para - arilo o hetero sustituidos
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
GT200300096A (es) Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
SV2009003235A (es) Triazoles biciclicos como moduladores de la proteina cinasa ref. x-18476m
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
PA8493701A1 (es) Compuestos para tratar la obesidad
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
GT200600429A (es) Compuestos organicos
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos